INTRODUCTION
Chronic spontaneous urticaria (CSU) (also known as chronic idiopathic urticaria) is defined as the occurrence of wheals (hives), angioedema or both for 6 weeks or longer due to known or unknown causes (Zuberbier 2014) CSU affects a patient's ability to perform activities of daily life and impacts work, causes sleep disturbances, emotional problems and loss of energy, ultimately affecting patients' quality of life (QoL) (Baiardini 2011 , Staubach 2006 The burden of CSU has been assessed by different categories of patient-reported outcomes (PRO) instruments (generic, dermatological or disease-specific)
The Urticaria Activity Score (UAS) is a daily diary which assesses key urticaria symptoms and signs (pruritus and hives). Twice-daily pruritus and hives ratings are averaged to create a daily UAS score which is summed over 7 days (UAS7) (Mathias 2012 , Zuberbier 2014 ). UAS7 score ranges from 0 to 42, with higher scores reflecting worse urticaria The UAS7 score is commonly used to assess the CSU disease activity (Mlynek 2008 ) and has been recommended by guidelines for routine clinical practice to determine disease activity and response to treatment (Zuberbier 2014) Dermatology Life Quality Index (DLQI) is a ten-question dermatologic QoL instrument resulting in a score that ranges from 0 to 30 and increases with greater QoL impairment (Finlay 1994). It has been validated for use in CSU patients (Lennox 2004) A recent study showed the significance of DLQI scores in terms of impact on patient's life (Hongbo 2005 Five CSU disease health states were defined using UAS7 scores (based on expert opinion):
-Urticaria-free: UAS7=0 -Well-controlled urticaria: UAS7=1-6 -Mild urticaria: UAS7=7-15 -Moderate urticaria: UAS7=16-27 -Severe urticaria: UAS7=28-42
Comparisons were made between the UAS7 health states and the following variables: DLQI, use of diphenhydramine pills at baseline and 12 weeks, presence of angioedema at baseline, and two questions from the patient daily diary: sleep interference and daily activity interference
Sleep interference and daily activity interference have a weekly score ranging from 0 to 21 with higher score meaning higher interference
Chi-square tests between the five UAS7 health states and the validated DLQI ranges were used to show the relationship between patients' urticaria symptoms and signs as measured by the UAS7 and dermatologic QoL using DLQI categories
Mean DLQI scores were compared between adjacent UAS7 health states to understand the impact of increased urticaria severity on patients' QoL
Mean scores for each of the comparison variables were calculated for each UAS7 health state. No tests of significant differences were calculated because of violations of multiplicity. Instead, patterns of differences in scores with worsening health states were examined
The analysis was reproduced for each trial separately and they were consistent across trials. Only results from GLACIAL trial are presented here
ReSULTS
At baseline, all the patients had only moderate or severe disease as defined by UAS7 scores Angioedema was present in 53% of patients at baseline Figure 2 summarises the mean levels of variables at baseline with higher mean scores for severe urticaria 
CONCLUSIONS
The results of the study suggest that the disease health states defined by UAS7 score ranges, can be further described using other parameters such as DLQI, interference with sleep and daily activities, use of rescue medication and presence of angioedema. This allows the understanding of the impact of each disease state on patient's life Urticaria-free health state was correlated with no effect on patients' lives and further described by almost no interference with sleep and daily activities, little need for rescue medication and almost no presence of angioedema Higher severity of UAS7 health state was associated with a greater impact on patients such as high impairment in QoL, high interference with sleep and daily activities, increased need for rescue medication and presence of angioedema Distinct and easily reproducible CSU health states can be efficiently described by categorizing the continuous (0-42) UAS7 into five ranges of scores which have been shown to correlate with QoL and other aspects of patient experience with urticaria Results were consistent across three clinical trials, lending confidence to the findings
